الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 91 |  |  |
| | | from | 91 | | |
Abstract
Globally, lung cancer is the leading cause of cancer related mortality. In Egypt it is the fourth cause of cancer deaths. Majority of the patients present with advanced disease.
Numerous oncogenic driver mutations have been found in NSCLC over the past ten years. This has made it possible to categorize this disease into therapeutically useful molecular subgroups, leading to the creation of new treatments that directly target mutated proteins and the associated signaling pathways, resulting in better clinical outcomes. Some studies have shown that lung cancer genetic profiles vary with race and ethnicity.
The purpose of this study was to determine the genetic profile of non-small cell lung cancer patients seen at the Alexandria oncology department. The study also aimed at finding out the clinicopathologic characteristics and estimated survival time of these patients.
We detected mutations in 28.3% of the samples. EGFR was the most frequently detected mutation in 16.7 % of the patients. Other mutations detected include ALK (3.33%) and ROS 1 (3.33%). BRAF, KRAS, NRAS and NTRK were each detected in 1.7% of the samples. Complex EGFR mutation and coexisting EGFR/ROS1 mutation were also detected in 1.7 % of the samples.
Majority of the patients were below 60 years of age and males were more represented than females. Most of the patients had adenocarcinoma histology and presented with advanced disease. The median PFS was 6 months, range (3–20) months and the median overall survival was 9 months, range (4–26) months.
Our results showed that the lung genetic profile was similar to that of Caucasian patients. However, KRAS mutations had a lower incidence. This study pointed out the importance of genetic testing in non -small cell cancer so as to administer a tailored and more beneficial treatment to